Chantal van Gils is Vice President, Evidence & Value at SSI Strategy and a senior life sciences strategist with more than 20 years of experience across academia, industry, and CRO environments. A physician-scientist by training, she specializes in designing and delivering integrated evidence strategies that align clinical development with regulatory, HTA, payer, and commercial requirements. Chantal has led over 100 global and regional programs across oncology, rare diseases, and advanced therapies, with deep expertise in real-world evidence, health economic modeling, and market access. She is recognized for translating complex evidence needs into actionable strategies that support regulatory approval, reimbursement success, and long-term commercial value.

Sigrid Klaar is a Medical Advisor and Advisory Board Member with extensive experience in oncology, EU regulation, and health technology assessment. An MD, PhD, and board-certified oncologist. She spent 14 years as a clinical assessor at the Swedish Medical Products Agency, working within the EMA system on oncology marketing authorisation applications and scientific advice, and as a Member and Vice Chair of the EMA Oncology Working Party, contributing to EU oncology guidelines.  She later joined the Dental and Pharmaceutical Benefits Agency (TLV), supporting national reimbursement decisions, EUnetHTA joint clinical assessments, and implementation of the EU HTA Regulation.

Sigrid supports pharmaceutical companies with regulatory and HTA strategy, advisory boards, and education on the EU HTA Regulation.

Ingela Loell is a Scientific Editor at SSI Strategy with more than 10 years of experience in scientific and regulatory communication. Holding a Ph.D. in Rheumatology from Karolinska Institutet, she specializes in translating complex biomedical science into clear, structured content for biotech and pharmaceutical audiences. Her work includes thought leadership, regulatory intelligence, and scientific documentation, developed in close collaboration with subject matter experts. She also supports AI-enabled innovation initiatives focused on improving the quality and efficiency of scientific content development.